A5037978088- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- Colorectal Cancer Surgical Treatments
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Bone health and treatments
- BRCA gene mutations in cancer
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Hormonal and reproductive studies
- Glioma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Testicular diseases and treatments
- Phagocytosis and Immune Regulation
- Colorectal Cancer Screening and Detection
- Polyomavirus and related diseases
- Synthesis and biological activity
- Renal and related cancers
- Multiple Myeloma Research and Treatments
Newcastle upon Tyne Hospitals NHS Foundation Trust
2015-2024
National Health Service
2024
Freeman Hospital
2011-2023
Hôpital Sahloul
2022
Institute of Cancer Research
2019
Ospedale Santa Maria
2017
National Physical Laboratory
2017
Liverpool Hospital
2017
North Staffordshire Clinical Commissioning Group
2015
James Cook University Hospital
2012
Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) men with germline BRCA1/2 mutations.
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
Lynch syndrome is a rare familial cancer caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging increase risk of early-onset aggressive prostate The IMPACT study prospectively assessing prostate-specific antigen (PSA) screening men with germline variants. Here, we report usefulness PSA screening, incidence, tumour characteristics after first round...
To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended for phase II studies, explore its efficacy. We assessed toxicities explored activity drug combination exclusively patients with malignant pleural mesothelioma (MPM). The pharmacokinetics both agents was investigated.Twenty-seven (23 male, four female) MPM were treated on five escalating levels. Doses ranged from 400 mg/m(2) (as 10-minute intravenous infusion), followed by...
The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, no consensus on the optimal time from to chemotherapy.
Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, associated cumulative toxicity, characterised by chronic often irreversible neuropathy. To assess efficacy of 3-month versus 6-month cancer to compare health-related quality life cost-effectiveness durations. An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial. A total 244...
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus usually given 6 (6 adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or III cancer were followed up for 3–8 years. within-trial analysis from a UK health-care perspective presented using resource use data, quality life (EQ-5D-3L),...
The purpose of this study was to determine activity temozolomide combined with paclitaxel or epothilone B in vitro, and investigate the combination a Phase I clinical trial. Melanoma cell lines A375P DX3 were treated either B. Combination indices determined assess degree synergism. In study, 21 patients malignant melanoma increasing doses (orally, days 1–5), fixed dose (i.v. infusion day 1), followed by escalation latter drug. Cycles treatment repeated every 3 weeks. Pharmacokinetics both...
To report the long-term outcomes from a longitudinal psychosocial study that forms part of 'Identification Men with genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher risk and controls' (IMPACT) study. The IMPACT is multi-national targeted prostate cancer (PrCa) screening individuals known germline pathogenic variant (GPV) either BReast CAncer gene 1 (BRCA1) or 2 (BRCA2).
Background: The patient pathway for muscle invasive bladder cancer (MIBC) is multidisciplinary. Trans-urethral resection of tumour (TURBT) counts as the first definitive treatment and subsequent therapy thereafter often delayed, which may adversely affect outcome. We elected to scrutinise management in detail understand these delays improve experience. Method: A retrospective mapping analysis was conducted on 17 patients with MIBC. causes any measures avoid were identified. prospective study...
147 Background: Anti-androgen manipulation (AA) is considered the standard initial therapy for high-risk/metastatic prostate cancer. The role of chemotherapy and anti-androgen (TAA) still undefined in this group. GenTax a phase II trial investigating clinical outcome gene profiling cancer before after AA or TAA. Here we present data. Methods: Patients with T3/4 disease, PSA ≥ 50 ng/ml Gleason score 8, metastatic disease were enrolled. randomised at histological diagnosis to TAA (goserelin...
403 Background: Functional imaging techniques which evaluate early treatment responses may identify non-responders who would benefit from a switch in therapy. This is prospective feasibility study of serial diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI scanning patients undergoing neoadjuvant chemotherapy for muscle-invasive bladder cancer. Methods: Scans were performed before during (10-17 days after the first second cycles). A repeatability DW-MRI scan was acquired on...
455 Background: Sunitinib gained NICE approval in March 2009 as first line treatment for metastatic renal cell carcinoma (mRCC) and UK experience of use is growing. The North England Cancer Network (NECN) was the cancer network to approve July 2007 has longest with this drug. clinical outcomes NECN patients are presented. Methods: Data collected analysed regarding all started on from 01/07/2007 30/09/2010. Follow up extended 28/02/2011. Previously published predictors response were compared...
223 Background: Radium (Ra-223) is a FDA and EMA approved alpha particle radiopharmaceutical used to treat men with metastatic castrate resistant prostate cancer (mCRPC) symptomatic bone metastasis. In view of emerging systemic options, new 2018 licence indication for 3 rd line onwards. We aim evaluate the impact therapy sequencing on survival outcomes from heterogeneous cohort 228 patients treated Ra-223 in single UK centre. Methods: prospectively collected data underwent mCRPC between...
259 Background: Androgen deprivation therapy has been the standard of care for advanced prostate cancer many years. However recent studies have reported a survival benefit upfront docetaxel chemotherapy in men with hormone sensitive cancer. The GenTax trial was single institution phase II study investigating clinical outcome and gene profiling patients treatment naïve treated either plus androgen (D+ADT) or alone (ADT). We report on updated data this trial. Methods: Patients newly diagnosed...
Idiopathic Intracranial Hypertension (IIH) is characterized by increased intracranial pressure,normal cerebrospinal fluid (CSF) content, and a normal brain imaging. Several medicationshave been implicated in hypertension. Renal transplant patients seem moresusceptible to develop IIH due the use of multi-drug immunosuppression steroid.
380 Background: Testicular malignancy is the most common cancer affecting men aged between 15 and 44 years. In our centre, almost all low-risk seminoma (LRS) stage-I non-seminomatous germ cell tumours (NSGCT) stage I (high low-risk) are followed-up on a surveillance program (SP) for minimum of 5 LRS patients scanned at 4, 6, 12 monthly intervals during years 1, 2, 3 to respectively. NSGCT undergo computer tomography (CT) scan in 1 4 year 6 thereafter. Clinical examination, Chest X-ray (CXR)...
133 Background: Survival in prostate cancer is increasing due to advances hormonal therapy. The recommended duration of Androgen Deprivation Therapy (ADT) 18 months or more for patients with Non-Metastatic (NM) high risk disease, and lifelong Metastatic disease. ADT is, however, an independent factor osteoporosis, a disease characterised by low Bone Mineral Density (BMD) subsequent increased fractures, which can lead significant disability early death. In advanced cancer, it therefore that...